Effect of alprostadil in the treatment of intensive care unit patients with acute renal injury

Table 1 Baseline data were compared between the two groups

Group	n	Year	Sex		Basic diseases				APACHE ІІ	AKI
			Men	Women	Trauma	Cardiovascular disease	Cerebrovascular disease	Other		ІІ	Ш
Alprostadil group	50	61.7 ± 8.0	29	21	13	10	20	7	23.6 ± 2.7	29	21
Control group	50	60.4 ± 10.3	32	18	15	6	23	5	24.0 ± 2.5	33	17
t/χ2		0.705	0.378		1.676				-0.769	0.679
P		0.483	0.539		0.642				0.444	0.410

APACHE II: Acute Physiological Function and Chronic Health Score II; AKI: Acute renal injury.

Table 2 Comparison of serum creatinine, blood urea nitrogen and kidney injury molecule-1 levels between the two groups (mean ± SD)

Group	n	Scr (μmol/L)		BUN (mmol/L)		KIM-1 (pg/mL)
		Before treatment	7 d after treatment	Before treatment	7 d after treatment	Before treatment	7 d after treatment
Alprostadil group	50	448.1 ± 95.2	180.6 ± 34.7ab	17.8 ± 3.9	8.1 ± 1.8ab	1338.2 ± 202.1	787.4 ± 144.2ab
Control group	50	420.8 ± 81.7	207.1 ± 42.4a	17.3 ± 3.4	9.3 ± 2.0a	1310.3 ± 231.8	855.8 ± 153.9a
T value		1.539	-3.420	0.683	-3.154	0.642	-2.293
P value		0.127	0.001	0.496	0.002	0.523	0.024
Group	n	NAGL (ng/mL)		IL-8 (ng/mL)
		Before treatment	7 d after treatment	Before treatment	7 d after treatment
Alprostadil group	50	126.9 ± 16.4	89.5 ± 11.0ab	58.3 ± 9.1	36.8 ± 7.0ab
Control group	50	130.0 ± 20.1	96.7 ± 12.4a	56.8 ± 8.3	41.0 ± 8.3a
T value		-0.845	-3.071	0.861	-2.735
P value		0.400	0.003	0.391	0.007

^aP < 0.05, compared with this group before treatment.

^bP < 0.05, compared with the control group. Scr: Serum creatinine; BUN: Blood urea nitrogen; KIM-1: Kidney injury molecule-1; NAGL: Neutrophil gelatinase-associated lipocalin; IL-8: Interleukin-8.

Table 3 Comparison of renal function indices between the two groups (mean ± SD)

Group	n	Renal resistance index		Partial pressure of oxygen in urine (mmHg)
		Before treatment	7 d after treatment	Before treatment	7 d after treatment
Alprostadil group	50	0.74 ± 0.06	0.65 ± 0.05ab	51.32 ± 10.32	65.06 ± 9.04ab
Control group	50	0.73 ± 0.07	0.68 ± 0.06a	52.40 ± 9.64	59.25 ± 8.75a
T value		0.767	-2.716	-0.541	3.265
P value		0.445	0.008	0.590	0.002

^aP < 0.05, compared with this group before treatment.

^bP < 0.05, compared with the control group.

Table 4 Comparison of clinical effect between two groups, n (%)

Group	n	Cure	Improve	Ineffective
Alprostadil group	50	32 (64.00)	14 (28.00)	4 (8.00)
Control group	50	21 (42.00)	22 (44.00)	7 (14.00)
Z value		-2.154
P value		0.031

Table 5 Comparison of urine volume recovery time and adverse reactions between the two groups

Group	n	Injection spot ache	Abdominal distention	Incidence of adverse reactions (%)
Alprostadil group	50	2	4	6 (12.00)
Control group	50	0	2	2 (4.00)
χ2 value				2.174
P value				0.14